Investor

SV Life Sciences

Last cheque observed Mar 2017. Silence since then is not evidence of inactivity: our sources miss unannounced rounds.

QuietNew fund $421M, Mar 2022VC firm

Series BSeries ASeries C

Cheques on record
0%of best year0cheques in 12 months, 121 on record
Since the last cheque3507days00hrs00min00sec
Median round$30MRounds led0 of 121Sole investor5 roundsExits13 from the portfolioMostly inUnited States, 69%
Pitch SV Life Sciences

SV Life Sciences highlights

  1. 01

    121 rounds on record

  2. 02

    Mostly Series B and Series A: 58% of its rounds

  3. 03

    Sole investor in 5 rounds, median $12M

  4. 04

    13 exits from the portfolio

What they do

Type
VC firm (from a list, unverified)
Cheque size
Not stated
Cold pitches
Not stated

The record

Every round we can evidence, newest first121 appearances

  1. 2017

    1 round

  2. Mar
    PulmocideSeries B · GB · Techcitynews$30MSole investor
  3. 2016

    2 rounds

  4. Sept
    Artios PharmaSeries A · GB · FinSMEs$33MWith 1 other
  5. Aug
    Aligned TeleHealthSeries A · US · FinSMEs$12MWith 1 other
  6. 2015

    5 rounds

  7. Aug
    ReShape MedicalSeries D · US$38MWith 5 others
  8. Aug
    AvitideSeries C · US$7.6MWith 4 others
  9. Jul
    KalVista PharmaceuticalsSeries B · GB$33MWith 4 others
  10. Jul
    Autifony TherapeuticsSeries A · GB$12MWith 4 others
  11. Jan
    Schweiger DermatologySeries A · US$12MSole investor
  12. 2014

    10 rounds

  13. Dec
    CardioKinetixSeries F · US$50MWith 4 others
  14. Oct
    Bicycle TherapeuticsSeries A · GB$32MWith 4 others
  15. Sept
    AcuFocusVenture · US$21MWith 5 others
  16. Jul
    EBR SystemsVenture · US$20MWith 5 others
  17. Jun
    Spinal KineticsVenture · US$34MWith 4 others
  18. May
    CardioFocusDebt · US$2.4MWith 7 others
  19. Apr
    PanOpticaSeries B · US$45MWith 2 others
  20. Feb
    Thesan PharmaceuticalsSeries B$49MWith 6 others
  21. Jan
    AqueSysSeries D · US$44MWith 4 others
  22. Jan
    TopiVertVenture · GB$6.8MWith 3 others
  23. 2013

    12 rounds

  24. Dec
    CSA MedicalSeries C · US$16MWith 6 others
  25. Dec
    Sutro BiopharmaSeries D · US · finsmes.com$26MWith 5 others
  26. Nov
    PulmocideSeries A · GB · finsmes.com$28MWith 4 others
  27. Nov
    Catabasis PharmaceuticalsSeries B · US · finsmes.com$32MWith 4 others
  28. Nov
    Delenex TherapeuticsSeries A · CH · startupticker.ch$8.0MWith 4 others
  29. Sept
    Affinium PharmaceuticalsDebt · US · canadianprivateequity.com$12MWith 2 others
  30. Sept
    ArsanisSeries B · AT · biospace.com$20MWith 3 others
  31. Jul
    OncoEthixSeries B · CH · finsmes.com$19MWith 3 others
  32. Jun
    WellNow Urgent Care HoldingsSeed · US$4.1MSole investor
  33. Mar
    CardioKinetixSeries E · US · finsmes.com$23MWith 4 others
  34. Feb
    Catabasis PharmaceuticalsVenture · US · fiercebiotech.com$9.0MWith 3 others
  35. Jan
    Ocular TherapeutixSeries D · US · businesswire.com$24MWith 3 others
  36. 2012

    11 rounds

  37. Dec
    Bicycle TherapeuticsGB · finsmes.com$6.0MWith 4 others
  38. Oct
    Health EssentialsUS · finsmes.comUndisclosedWith 1 other
  39. Oct
    ReShape MedicalSeries C · US · pevc.dowjones.com$15MWith 2 others
  40. Oct
    CibiemSeries A · US · finsmes.com$10MWith 1 other
  41. Sept
    Karus TherapeuticsSeries B · GB · pevc.dowjones.com$7.6MWith 3 others
  42. Jul
    Cyterix PharmaceuticalsVenture · US$7.3MWith 1 other
  43. May
    Sutro BiopharmaSeries C · US · finance.yahoo.com$17MWith 4 others
  44. Apr
    AlloCureSeries B · US · masshightech.com$25MWith 2 others
  45. Apr
    Good Start GeneticsSeries B · US · masshightech.com$14MWith 2 others
  46. Apr
    AdimabSeries F · US · adimab.com$14MWith 2 others

An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.

The team

Named by the firm itself, on a filing, its Form ADV or its company registration12 named

DDDavid D. MilneMember of the GP LLCiFiling they signed
EDEugene D. Hill, IIIMember of the GP LLCiFiling they signed
EHEugene HillExecutive OfficeriFiling they signed
GMGreg MaddenExecutive OfficeriFiling they signed
HAHouman AshrafianExecutive OfficeriFiling they signed
JGJames GarveyMember of the GP LLCiFiling they signed
KDKate D. BinghamMember of the GP LLCiFiling they signed
LDLutz D. GiebelMember of the GP LLCiFiling they signed
MBMichael BalmuthExecutive OfficeriFiling they signed
MDMichael D. RossMember of the GP LLCiFiling they signed
PLPaul LaVioletteExecutive OfficeriFiling they signed
TFThomas FlynnExecutive OfficeriFiling they signed

We also hold 11 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.

Exits from the portfolio

Companies it backed that were later bought or listed13 in all

AqueSysBought by Allergan$300MSept 2015
AcceleCare Wound CentersBought by HealogicsUndisclosedMar 2015
Convergence PharmaceuticalsBought by Biogen Idec$675MJan 2015
OncoEthixBought by Merck & Co.UndisclosedDec 2014
SynarcBought by BioClinicaUndisclosedMar 2014
Affinium PharmaceuticalsBought by Debiopharm GroupUndisclosedFeb 2014
Rempex PharmaceuticalsBought by The Medicines Company$464MDec 2013
CadentBought by Align TechnologyUndisclosedMar 2011
Sadra MedicalBought by Boston Scientific$193MNov 2010
LensX LasersBought by AlconUndisclosedJul 2010
Phase ForwardBought by Oracle Corporation$685MApr 2010
CHF SolutionsBought by GambroUndisclosedJan 2010
Alantos PharmaceuticalsBought by AmgenUndisclosedJun 2007

An exit counts when it came after the firm's first round in the company. From historical deal records.

Companies it bought

Acquisitions by the firm itself

XimedicaUndisclosedNov 2014

Who they invest alongside

The investors most often in the same rounds as SV Life Sciences. A count of rooms they were both in, not a relationship either has claimed.

Accuitive Medical VenturesVC firm13rounds togetherVersant VenturesVC firm13rounds togetherNovo Holdings A/SGrowth equity12rounds togetherNew Leaf Venture PartnersVC firm10rounds togetherPolaris PartnersVC firm10rounds togetherThe Carlyle GroupPrivate equity10rounds togetherHBM BioVenturesGrowth equity9rounds togetherOrbiMedPrivate equity8rounds togetherClarus VenturesVC firm7rounds togetherSplit Rock PartnersVC firm7rounds togetherAlta PartnersVC firm6rounds togetherEssex Woodlands Healthcare PartnersVC firm6rounds together

Recently backed

The latest companies SV Life Sciences put money into.

Pulmocide$30M · Mar 2017Artios Pharma$33M · Sept 2016Aligned TeleHealth$12M · Aug 2016

Quick answers about SV Life Sciences

What does SV Life Sciences invest in?

SV Life Sciences invests most often at Series B and Series A (58% of the rounds on record).

How active is SV Life Sciences?

121 investments on record, 0 of them in the last 12 months. The most recent was in Mar 2017.

What has SV Life Sciences invested in recently?

Its most recent investments on record: Pulmocide (Series B, Mar 2017), Artios Pharma (Series A, Sept 2016) and Aligned TeleHealth (Series A, Aug 2016).

How big are SV Life Sciences's cheques?

The median round it joins is $30M.

Does SV Life Sciences lead rounds?

Rarely, if at all: none of its 121 investments on record names it as the lead.

Where does SV Life Sciences invest?

Most of the companies it backs are in the United States (69%), the United Kingdom (23%) and Switzerland (5%).

Is SV Life Sciences investing now?

No investments in the last 12 months; the latest was in Mar 2017.

Who does SV Life Sciences invest alongside?

Most often Accuitive Medical Ventures (13 rounds together), Versant Ventures (13 rounds together) and Novo Holdings A/S (12 rounds together).

Raising now?

Find the investors who back rounds like yours, and keep every conversation on one fundraising board.

Find similar investorsOpen your CRM

Built from the rounds we watched, its filings and its own website, refreshed every night. How we count · Report a correction · Is this your firm? Claim it